Your browser doesn't support javascript.
Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases.
Papagoras, Charalampos; Fragoulis, George E; Zioga, Nikoleta; Simopoulou, Theodora; Deftereou, Kleopatra; Kalavri, Eleni; Zampeli, Evangelia; Gerolymatou, Nafsika; Kataxaki, Evangelia; Melissaropoulos, Konstantinos; Panopoulos, Stylianos; Fragiadaki, Kalliopi; Evangelatos, Gerasimos; Bournia, Vasiliki-Kalliopi; Arida, Aikaterini; Karamanakos, Anastasios; Pappa, Maria; Panagiotopoulos, Alexandros; Koutsianas, Christos; Mparouta, Georgia; Dimitroulas, Theodoros; Liossis, Stamatis-Nick; Tektonidou, Maria G; Kravvariti, Evrydiki; Kougkas, Nikolaos; Georgiou, Panagiotis; Voulgari, Paraskevi; Elezoglou, Antonia; Bogdanos, Dimitrios P; Vassilopoulos, Dimitrios; Sfikakis, Petros P.
  • Papagoras C; First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece.
  • Fragoulis GE; Joint Academic Rheumatology Program, 1st Department of Propedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Zioga N; First Department of Internal Medicine, Democritus University of Thrace, Komotini, Greece.
  • Simopoulou T; Clinic of Rheumatology and Clinical Immunology, University Hospital of Larissa, Larissa, Greece.
  • Deftereou K; Fourth Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Kalavri E; Department of Rheumatology, Asklepieion General Hospital, Voula, Athens, Greece.
  • Zampeli E; Institute for Autoimmune Systemic and Neurological Diseases, Athens, Greece.
  • Gerolymatou N; Rheumatology Department, Iaso Hospital, Athens, Greece.
  • Kataxaki E; Rheumatology Clinic, University of Ioannina School of Medicine, Ioannina, Greece.
  • Melissaropoulos K; Rheumatology Department, General Hospital Elefsinas Thriaseio, Athens, Greece.
  • Panopoulos S; Department of Rheumatology, Agios Andreas Hospital, Patras, Greece.
  • Fragiadaki K; Joint Academic Rheumatology Program, 1st Department of Propedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Evangelatos G; Joint Academic Rheumatology Program, 1st Department of Propedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Bournia VK; Joint Academic Rheumatology Program, 1st Department of Propedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Arida A; Joint Academic Rheumatology Program, 1st Department of Propedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Karamanakos A; Joint Academic Rheumatology Program, 1st Department of Propedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Pappa M; Joint Academic Rheumatology Program, 1st Department of Propedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Panagiotopoulos A; Joint Academic Rheumatology Program, 1st Department of Propedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Koutsianas C; Joint Academic Rheumatology Program, Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, National and Kapodistrian University of Athens, Athens, Greece.
  • Mparouta G; Joint Academic Rheumatology Program, Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, National and Kapodistrian University of Athens, Athens, Greece.
  • Dimitroulas T; Private Rheumatology Office, Karditsa, Greece.
  • Liossis SN; Fourth Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Tektonidou MG; Department of Internal Medicine, University of Patras Medical School, Patras, Greece.
  • Kravvariti E; Joint Academic Rheumatology Program, 1st Department of Propedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Kougkas N; Joint Academic Rheumatology Program, 1st Department of Propedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Georgiou P; Fourth Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Voulgari P; Department of Rheumatology, Agios Andreas Hospital, Patras, Greece.
  • Elezoglou A; Rheumatology Clinic, University of Ioannina School of Medicine, Ioannina, Greece.
  • Bogdanos DP; Department of Rheumatology, Asklepieion General Hospital, Voula, Athens, Greece.
  • Vassilopoulos D; Clinic of Rheumatology and Clinical Immunology, University Hospital of Larissa, Larissa, Greece.
  • Sfikakis PP; Joint Academic Rheumatology Program, Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, National and Kapodistrian University of Athens, Athens, Greece.
Ann Rheum Dis ; 81(7): 1013-1016, 2022 07.
Article in English | MEDLINE | ID: covidwho-1511430
ABSTRACT

OBJECTIVE:

Τo report outcomes of breakthrough COVID-19 in comparison with COVID-19 in unvaccinated patients with systemic rheumatic diseases (SRDs).

METHODS:

Patients with SRD with COVID-19 (vaccinated and unvaccinated) were included by their rheumatologists in a registry operated by the Greek Rheumatology Society in a voluntarily basis. Type, date and doses of SARS-CoV-2 vaccines were recorded, and demographics, type of SRD, concurrent treatment, comorbidities and COVID-19 outcomes (hospitalisation, need for oxygen supplementation and death) were compared between vaccinated and unvaccinated patients.

RESULTS:

Between 1 March 2020 and 31 August 2021, 195 patients with SRD with COVID-19 were included; 147 unvaccinated and 48 vaccinated with at least one dose of a SARS-CoV-2 vaccine (Pfizer n=38 or AstraZeneca n=10). Among vaccinated patients, 29 developed breakthrough COVID-19 >14 days after the second vaccine dose (fully vaccinated), while 19 between the first and <14 days after the second vaccine dose (partially vaccinated). Despite no differences in demographics, SRD type, treatment or comorbidities between unvaccinated and vaccinated patients, hospitalisation and mortality rates were higher in unvaccinated (29.3% and 4.1%, respectively) compared with partially vaccinated (21% and 0%) or fully vaccinated (10.3% and 0%) patients.

CONCLUSIONS:

Vaccinated patients with SRD with breakthrough COVID-19 have better outcomes compared with unvaccinated counterparts with similar disease/treatment characteristics.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Rheumatic Diseases / COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: Ann Rheum Dis Year: 2022 Document Type: Article Affiliation country: Annrheumdis-2021-221539

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Rheumatic Diseases / COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: Ann Rheum Dis Year: 2022 Document Type: Article Affiliation country: Annrheumdis-2021-221539